Renalytix (RENX) Registration Filing summary

Company overview and business model

• Focuses on providing AI-enabled prognostic tests to identify patients at risk of progressive kidney disease, aiming to enable early intervention and reduce the burden of chronic kidney disease globally.

• Flagship product, kidneyintelX.dkd, is the first FDA-authorized in vitro prognostic test for assessing risk of kidney function decline, developed through collaborations with leading medical institutions.

• Operates internationally, with principal offices in the UK and US, and leverages technology licensed from major research centers.

Financial performance and metrics

• Raised approximately $12 million in gross proceeds from a two-tranche private placement in March and April 2024.

• Additional capital raised through a registered direct offering and an at-the-market facility with up to $15 million in potential proceeds.

• Most recent audited financials (June 30, 2023) include a going concern warning from auditors.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling securityholders; all registration expenses are borne by the company.

• Proceeds from prior private placements used for general corporate purposes and working capital.